Introduction {#s1}
============

Opioids blunt both sensory-discriminative and affective-motivational dimensions of pain by modulating neuronal activity in the central and peripheral nervous systems ([@bib42]; [@bib62]; [@bib8]). The affective-motivational dimension of pain underlies the aversiveness and negative emotional affect that arise in response to activation of nociceptive inputs ([@bib14]; [@bib41]; [@bib53]). This study examines how opioids modulate the circuitry involved in affective-motivational pain perception.

In humans, affective pain perception is associated with increased activity in the medial thalamus, as well as the anterior cingulate cortex (ACC) ([@bib7]; [@bib9]; [@bib45]; [@bib46]). In rodents, chronic pain is associated with hypersensitivity of mediodorsal thalamic neurons to sensory stimuli ([@bib57]) and activation of the ACC has been shown to be aversive using a conditioned place aversion paradigm ([@bib23]). In contrast, lesions of the ACC decrease affective-motivational pain responses ([@bib22]). Anatomically, neurons from the medial thalamus (MThal) send glutamate afferents to the cortical regions, including the dorsal and ventral ACC, prefrontal cortex (PFC) and insular cortices ([@bib19]), as well as to the dorsomedial striatum (DMS) ([@bib20]). The ACC in turn projects to the DMS, forming a circuit connecting the MThal and the ACC, both of which provide convergent glutamate inputs to the DMS. This thalamo-cortico-striatal circuit has been demonstrated to be involved in pain processing, in particular, affective pain perception ([@bib48]; [@bib47]; [@bib12]; [@bib61]; [@bib60]).

Clinically, opioids are used to reduce pain perception by modulating both sensory-discriminative and affective-motivational aspects of pain. Mu-opioid receptors (MORs) and delta-opioid receptors (DORs) are predominantly expressed in the mediodorsal (MD) thalamus and ACC, respectively ([@bib33]; [@bib11]). Injection of opioids into the MD or ACC can relieve pain and induce conditioned place preference in an animal model of chronic pain ([@bib6]; [@bib15]; [@bib39]), suggesting a role for opioid modulation of thalamic and cortical circuitry in affective pain.

The striatum is enriched in MORs and DORs, as well as the endogenous opioid ligand enkephalin ([@bib44]; [@bib27]). Also, opioids have been shown to inhibit glutamate inputs to the striatum, as well as GABA release from local striatal circuitry ([@bib21]; [@bib18]; [@bib5]; [@bib35]; [@bib1]; [@bib2]). In this context, the striatum serves as a potentially critical hub for opioid-dependent modulation of fast synaptic transmission in the affective pain circuitry ([@bib62]).

The current work determines how and where opioids modulate synaptic transmission between the thalamic, cortical and striatal regions that are important for the perception of affective pain. Results revealed opposing roles of the MORs and DORs regarding information flow from the thalamus to the striatum, whereby MOR activation decreased glutamate transmission in the striatum, while DOR activation facilitated glutamate transmission via disinhibition of cortical pyramidal neurons. Thus, MOR and DOR activation are predicted to play opposing roles in pain processing mediated by the thalamo-cortico-striatal circuit. Together, these data identify specific synaptic connections within the thalamo-cortico-striatal circuit that are modulated by opioids and illustrate how different opioid subtypes can independently modulate neuronal communication at the circuit level.

Results {#s2}
=======

Opioid receptor agonists suppress excitatory transmission in the dorsomedial striatum {#s2-1}
-------------------------------------------------------------------------------------

Because the DMS mediates learning and expression of motivated behaviors in response to both aversive and rewarding stimuli, the opioid sensitivity of glutamate afferents in the DMS was investigated. In acute mouse brain slice preparations, individual striatal medium spiny neurons (MSNs) were identified based on physiological properties ([@bib28]). Whole-cell voltage-clamp recordings were obtained and glutamate release was evoked using electrical stimulation. AMPA receptormediated excitatory postsynaptic currents (EPSCs) were pharmacologically isolated and recorded ([Figure 1---figure supplement 1a--c](#fig1s1){ref-type="fig"}). Similar to previously published results in the nucleus accumbens and dorsolateral striatum, application of the mu- and delta-selective opioid agonist \[Met^5^\]-enkephalin (ME, 3 µM) significantly decreased the amplitude of the EPSCs. This inhibition was reversed upon washout of ME ([Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"}; ME: 77.8 ± 4.6% of baseline; washout: 90.5 ± 2.6% of baseline; baseline vs ME: W(11) = 1, p\<0.01) ([@bib21]; [@bib18]; [@bib5]). The AMPA receptor antagonist NBQX (3 µM) eliminated the evoked currents ([Figure 1---figure supplements 1c](#fig1s1){ref-type="fig"} and 4.0 ± 2.6% of baseline; baseline vs NBQX: W(5) = 0, p\<0.05).

Mu-opioid receptor agonists suppress thalamic but not cortical glutamatergic inputs to the dorsomedial striatum {#s2-2}
---------------------------------------------------------------------------------------------------------------

Anatomic mapping in mice indicated that glutamate inputs from the medial thalamus and ACC converged in the DMS ([Figure 1a--b](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1d--e](#fig1s1){ref-type="fig"}) ([@bib20]). In addition, MORs and DORs appear to be enriched in the medial thalamus and midline cortical structures (including the ACC), respectively ([@bib11]; [@bib56]). To test whether anatomically distinct expression of MORs and DORs in the thalamus and the cortex confer specific opioid sensitivity to these two inputs to the striatum, an optogenetic approach was used to isolate the specific thalamic and cortical inputs onto MSNs in the DMS. Recombinant adeno-associated viruses (AAVs) encoding two optically-separable channelrhodopsin variants were injected into the MThal and ACC of three- to five-week-old mice ([Figure 1a](#fig1){ref-type="fig"}). The blue light-sensitive channelrhodopsins (CsChR or ChR2(H134R)) were expressed in the MThal while the red light-sensitive channelrhodopsin (Chrimson) was expressed in the ACC ([@bib37]; [@bib26]). Expression of one channelrhodopsin variant alone demonstrated wavelength-selectivity of optically-evoked excitatory postsynaptic currents (oEPSCs) in response to brief pulses of either blue (470 nm) or red (625 nm) light, and minimal cross-contamination from undesired light stimulation was observed under these conditions ([Figure 1---figure supplement 1d--e](#fig1s1){ref-type="fig"}). Following co-expression of Chrimson in the ACC and either CsChR or ChR2(H134R) in the MThal, illumination with both blue (470 nm, MThal inputs) and red light (625 nm, ACC inputs) evoked robust oEPSCs in individual MSNs in the DMS ([Figure 1b](#fig1){ref-type="fig"}). The MOR-selective agonist DAMGO inhibited oEPSC amplitude to MThal stimulation (470 nm light) in a reversible manner, and did not alter oEPSC amplitude to ACC stimulation ([Figure 1c](#fig1){ref-type="fig"}; DAMGO I~MThal~: 38.2 ± 6.1% of baseline, *z* = 4.738, p\<0.001; I~ACC~: 92.8 ± 4.9%, *z* = 0.459, p=0.647). These observations demonstrated both the optical separation of the thalamic and cortical inputs and the ability of MOR agonists to selectively inhibit excitatory MThal inputs. Despite the apparent expression of DORs in the midline cortical regions, DOR activation by its selective agonist DPDPE did not inhibit the ACC, or MThal inputs ([Figure 1b--d](#fig1){ref-type="fig"}; DPDPE I~MThal~: 99.6 ± 5.7% of baseline, *z* = 0.106, p=0.916; I~ACC~: 95.6 ± 2.6%, *z* = 0.196, p=0.845).

![Mu-opioid agonists suppress thalamic but not cortical inputs to single MSNs in the striatum.\
(**a**) Schematic (upper panel) and an acute mouse brain slice example (lower panel) of viral injection design and the axonal projections to the striatum, respectively. Overlaid brightfield and epifluorescent images showing the injection site of Chrimson (left image, red) in the ACC, and CsChR (right image, cyan) in the MThal, and convergent axonal projections from both injections to the DMS (center image). (**b**) Schematic (upper panel) and representative recordings (lower panel) for optical excitation. (**c**) Example oEPSCs of individual MSNs evoked by 625 nm (from the ACC, upper traces), and by 470 nm (from the MThal, lower traces) light pulses. The MOR (orange label) agonist DAMGO (1 µM) was perfused followed by the MOR antagonist CTAP (1 µM). Following CTAP, the DOR (teal label) agonist DPDPE (1 µM) was perfused followed by the moderately-selective DOR antagonist naltrindole (0.3 µM). Red bars: 3 ms of 625 nm light stimulation; blue bars: 1 ms of 470 nm light stimulation. (**d**) Summary data of dual wavelength excitation of the ACC and MThal input oEPSCs recorded from single MSNs. Data are plotted as the percentage of baseline current following exposure to DAMGO or DPDPE for inputs from the ACC and MThal (N = 5, n = 8, Linear mixed model: 3-way interaction, opioid type (mu vs. delta opioid) x input source (ACC vs. MThal) x drug condition (baseline vs. agonist vs. antagonist), F (4,8)=2.938, p=0.091; MThal~baseline\ x\ DAMGO~: *z* = 4.738, p\<0.001; MThal~baseline\ x\ DAMGO~ vs. ACC~baseline\ x\ DAMGO~; *z* = −3.026, p\<0.01). Mean ± standard error of the mean. Str: striatum.](elife-45146-fig1){#fig1}

Similar results were obtained when Chrimson and CsChR were injected into the MThal and the PFC, respectively ([Figure 1---figure supplement 1f--g](#fig1s1){ref-type="fig"}). DAMGO decreased oEPSC amplitude from the MThal inputs while it had no effect on oEPSCs from the PFC inputs ([Figure 1---figure supplement 1h--i](#fig1s1){ref-type="fig"}; DAMGO I~MThal~: 22.2 ± 3.7% of baseline, *z* = 3.497, p\<0.001; I~PFC~: 93.9 ± 5.6%, *z* = 0.052, p=0.958). DPDPE produced no significant changes in oEPSC amplitude from either input (DPDPE I~MThal~: 96.5 ± 3.9% of baseline, *z* = 0.087, p=0.931; I~PFC~: 81.6 ± 3.9%, *z* = 0.672, p=0.502). These results indicate that MThal glutamate inputs onto MSNs were preferentially inhibited by activation of MORs, while DOR agonists had little to no modulatory effect on the MThal, ACC, or PFC inputs to the MSNs in the DMS. These findings of mu- and delta-opioid specificity were further confirmed with similar experiments using single channelrhodopsin variant viral injections into the ACC, PFC, or MThal ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

To ensure that these opioid-sensitive inputs indeed originated from the MThal, *Slc17a6-cre* mice, which express Cre-recombinase in vGlut2-positive cells ([@bib55]), were injected with DIO-ChR2(H134R) virus which restricted the expression of ChR2 only to the thalamus ([@bib58]). Similar to the results from wild-type mice, activation of MORs by DAMGO, but not DORs by DPDPE, resulted in inhibition of the MThal inputs to the MSNs ([Figure 2](#fig2){ref-type="fig"}; I~DAMGO~: 18.1 ± 3.9% of baseline, W(6) = 0, p\<0.05; I~DPDPE~: 100.5 ± 7.9%, W(5) = 7, p=1). Furthermore, MOR agonists also inhibited inputs from the anterior medial thalamus, suggesting the general effects of opioid inhibition of thalamic inputs to the DMS ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

![Mu-opioid agonists selectively suppress thalamic inputs from vGluT2-positive thalamic neurons.\
(**a**) Example overlaid brightfield and epifluorescent images showing Cre-dependent expression of ChR2(H134R)-EYFP (cyan) in the MThal (left panel) and axonal projections into the DMS (right panel) following injection of AAV-DIO-ChR2(H134R)-EYFP in the MThal of *Slc17a6-Cre* mice, which express Cre-recombinase in vGluT2-positive cells. (**b**) Experimental schematic showing optical stimulation of glutamate inputs in the DMS (left panel). Representative traces of oEPSCs showing effects of MOR agonist DAMGO (1 µM, middle panel, orange) and antagonist naloxone (NLX, 1 µM, middle panel, black), and the DOR agonist DPDPE (1 µM, right panel, teal) and DOR antagonist naltrindole (0.3 µM, right panel, black). Blue bars: 1 ms of 470 nm light stimulation. (**c**) Summary data of oEPSCs showing effects of MOR agonist DAMGO and antagonist CTAP or NLX (1 µM), and the DOR agonist DPDPE and DOR antagonist naltrindole. DAMGO/(CTAP/NLX): N = 3, n = 6, *SM* = 9.33, p\<0.01; DPDPE/naltrindole, N = 3, n = 5, *SM* = 0, p=1.0. Skillings-Mack test followed by paired Wilcoxon signed-ranks test *post-hoc* analysis. Mean ± standard error of the mean. \*p≤0.05; *SM*: Skillings-Mack statistic; Str: striatum.](elife-45146-fig2){#fig2}

Thalamostriatal and thalamocortical projections can arise from the same medial thalamic neuronal population {#s2-3}
-----------------------------------------------------------------------------------------------------------

Single neuron tracing in the rat has demonstrated that medial thalamic neurons can send collaterals to both the cortex and striatum ([@bib43]; [@bib29]). To determine whether the opioid-sensitive population of thalamic neurons in mouse project to both the ACC and DMS, two approaches were used. First, red and green fluorescent retrograde transported beads (retrobeads) were injected into the ACC and DMS, respectively ([Figure 3---figure supplement 1b](#fig3s1){ref-type="fig"}). The injection sites were then localized based on the mouse brain atlas ([@bib13]), [Figure 3---figure supplement 1b--c](#fig3s1){ref-type="fig"}). Retrogradely labeled somas were found in the lateral MD and the central lateral (CL) thalamus ([Figure 3---figure supplement 1c--g](#fig3s1){ref-type="fig"}). In brain sections containing the MD thalamus (selected figures 44, 45, and 46 of the Franklin and Paxinos atlas, second edition; [Figure 3---figure supplement 1d](#fig3s1){ref-type="fig"}), there was a substantial fraction of neurons that projected to the DMS that also contained retrograde beads originating from the ACC (21 ± 4% of striatal-projecting neurons colocalized with ACC-projecting neurons). Second, to further determine whether cortical-projecting thalamic neurons send collateral axons to the striatum, a retrogradely transported virus, rAAV-retro ([@bib52]), encoding Cre-recombinase was injected into the ACC, along with AAV-GFP which served to indicate the injection site of rAAV2-retro-Cre virus and to visualize corticostriatal axons ([@bib32]; [@bib52]). In the same mice, Cre-dependent AAV-FLEX-TdTomato virus was injected into the MThal ([Figure 3a--d](#fig3){ref-type="fig"}). TdTomato would be expected to be expressed only in the thalamic neurons projecting to the ACC area that were also infected by rAAV-retro-Cre virus. Indeed, TdTomato-positive neurons were found in the MThal ([Figure 3b](#fig3){ref-type="fig"}). GFP expression in the ACC indicated the rAAV-retro virus injection site ([Figure 3c](#fig3){ref-type="fig"}), and TdTomato-expressing axon terminals, originating from thalamic neurons, were also visible in the ACC ([Figure 3c](#fig3){ref-type="fig"}). Prominent GFP-expressing axons originating from the ACC and TdTomato-expressing axon collaterals originating from the MThal were observed in the DMS ([Figure 3d](#fig3){ref-type="fig"}). These results indicate the existence of thalamic neurons that project to both the ACC and DMS, and further, that ACC-striatal and MThal-striatal projections can innervate anatomically overlapping areas in the DMS ([@bib20]).

![Individual mediodorsal thalamic neurons project to both the DMS and ACC.\
(**a**) Schematic of the rAAV-retro-Cre and Cre-dependent AAV-DIO-TdTomato injections. (**b**) Fluorescent image of cell bodies expressing TdTomato following injections shown in (**a**) in the MThal (magenta, right panel), with corresponding mouse brain atlas section (left panel). (**c**) Representative mouse brain atlas section showing approximate origin of images taken from ACC (left panels) and DMS as shown in (**d**). Images of the ACC showing AAV-GFP injection site and axons from the MThal (magenta). (**d**) Images of the DMS showing overlapping axons from both the ACC (green) and MThal (magenta). Rightmost panel shows high magnification image taken at the black box demarcation in the left panel. Cell nuclei are stained with DAPI (blue). (**e**) Schematic of retrograde rAAV-retro-Cre and Cre-dependent AAV-DIO-ChR2(H134R)-EYFP injections, and recordings of MSNs in the DMS. (**f**) An example trace of oEPSCs of a MSN in the DMS from a mouse injected as shown in (**e**). ME: opioid agonist \[Met^5^\]-enkephalin. Blue bars: 1 ms of 470 nm light stimulation. V: ventral; M: midline; Hb: habenula; CL: centrolateral thalamus; MD: mediodorsal thalamus; Str: striatum; lv: lateral ventricle. Mouse brain atlas sections from [@bib13].](elife-45146-fig3){#fig3}

To confirm that the apparent axon collaterals in the DMS form functional synapses rather than passing through the DMS en route to the ACC, rAAV-retro-Cre was injected into the ACC and a Cre-dependent ChR2-expressing virus AAV-DIO-ChR2(H134R)-EYFP was injected into the MThal, conferring the ability within the striatum to optogenetically activate potential thalamic axons originating from ACC-projecting MThal neurons ([Figure 3e](#fig3){ref-type="fig"}). Optical illumination evoked glutamate-mediated EPSCs in striatal MSNs that were potently inhibited by ME ([Figure 3f](#fig3){ref-type="fig"}; I~ME~: 22.4 ± 6.6% of baseline, N = 3, n = 5, paired t-test, p\<0.01). These data suggest the existence of an opioid-sensitive thalamic neuronal population projecting to both the DMS and ACC.

Mu-opioid agonists suppress excitatory thalamic inputs to the ACC, while delta-opioid agonists suppress feed-forward inhibition {#s2-4}
-------------------------------------------------------------------------------------------------------------------------------

Since the excitatory MThal inputs to the DMS were strongly inhibited by MOR activation and at least a fraction of those thalamic neurons project to both the ACC and DMS, we hypothesized that the excitatory MThal inputs to the ACC would be inhibited by MORs. Inputs from the MD thalamus have been reported to synapse directly onto layer 2/3 (L2/3) and 5 (L5) pyramidal neurons, and also to trigger GABA release onto pyramidal neurons via innervation of L2/3 and L5 parvalbumin-positive (PV) interneurons in the ACC ([@bib10]). Both optically evoked EPSCs and feed-forward inhibitory postsynaptic currents (oIPSCs) were measured in L2/3 and L5 pyramidal neurons of the ACC ([Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}; also see Materials and methods). Similar to the results from recordings of the MSNs in the DMS, oEPSCs of the L2/3 and L5 pyramidal neurons in the ACC from the MThal inputs were potently inhibited by the MOR agonist DAMGO but unaffected by the DOR agonist DPDPE, suggesting expression of MORs but not DORs on thalamic glutamate terminals in the ACC ([Figure 4b--c](#fig4){ref-type="fig"}, and [Figure 4---figure supplement 1b--c](#fig4s1){ref-type="fig"}; I~DAMGO~: 54.0 ± 5.0% of baseline, W(17) = 1, p\<0.001; I~DPDPE~: 93.4 ± 7.0%, W(14) = 36, p=0.312; L2/3; I~DAMGO~: 69.3 ± 3.3% of baseline, W(15) = 0, p\<0.001; I~DPDPE~: 92.9 ± 5.4%, W(9) = 9, p=0.129). These oEPSCs were of thalamic origin since track injection of ChR2 dorsal to the thalamus resulted in only sporadic and insignificant oEPSCs in the ACC ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

![Mu-opioid agonists suppress thalamic inputs to pyramidal neurons in the ACC while delta-opioid agonists suppress cortical feed-forward inhibition in the ACC.\
(**a--c**) oEPSCs of the pyramidal neurons in the ACC elicited by optical stimulation of MThal input. (**a**) Schematic of ChR2 injection, MThal optical stimulation, and recording of oEPSCs of the layer 5 (L5) pyramidal neurons (Pyr) in the ACC. Blue: ChR2 expression and optical stimulation. (**b**) Example traces of oEPSCs elicited from optical stimulation of the MThal terminals in the ACC during baseline (gray), application of DAMGO (1 µM, left panel, orange), followed by CTAP (1 µM, left panel, black), or application of DPDPE (1 µM, right panel, teal,) followed by naltrindole (0.3 µM, right panel, black). Blue bars: 1 ms of 470 nm light stimulation. (**c**) Summary data of oEPSCs of all recording as shown in (**b**) with responses plotted as a percent of the baseline. DAMGO: N = 13, n = 17; CTAP: N = 12, n = 14; *SM* = 22.85, p\<0.001; DPDPE: N = 11, n = 15; naltrindole: N = 5, n = 7, *SM* = 0.989, p=0.610. (**d--f**) oIPSCs of the pyramidal neurons from the MThal optical stimulation, via inhibition through interneurons in the ACC. (**d**) Schematic of ChR2 injection, MThal optical stimulation, and recording of the pyramidal neurons in the ACC via feed-forward inhibition. Blue: ChR2 expression and optical stimulation; magenta: outline of an interneuron. (**e**) Example traces of oIPSCs elicited from optical stimulation of the MThal terminals in the ACC during baseline (gray), application of DAMGO (1 µM, left panel, orange) followed by CTAP (1 µM, left panel, black), or application of DPDPE (1 µM, right panel, teal) followed by naltrindole (0.3 µM, right panel, black). (**f**) Summary data of oIPSCs for all recordings as in (**b**) with responses plotted as a percent of the baseline. DAMGO: N = 9, n = 14; CTAP, N = 7, n = 8, *SM* = 15.68, p\<0.001; DPDPE: N = 6, n = 12; naltrindole: N = 5, n = 7, *SM* = 7.426, p\<0.05. Skillings-Mack test followed by paired Wilcoxon signed-ranks test *post-hoc* analysis. \*p≤0.05; \*\*p≤0.01; \*\*\*p≤0.001. Mean ± standard error of the mean. *SM*: Skillings-Mack statistic; Blue bars: 1 ms of 470 nm light stimulation.](elife-45146-fig4){#fig4}

Surprisingly, both DAMGO and DPDPE potently inhibited GABA-mediated oIPSCs from the MThal to the ACC pyramidal neurons ([Figure 4e--f](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1e--f](#fig4s1){ref-type="fig"}; I~DAMGO~, 37.9 ± 7.8% of baseline, W(14) = 0, p\< 0.001; I~DPDPE~, 47.6 ± 7.9%, W(11) = 1, p\<0.01; I~DAMGO~, 61.2 ± 9.5% of baseline, W(12) = 1, p\<0.001; I~DPDPE~, 62.7 ± 5.4%, W(10) = 0, p\<0.01). To confirm the DPDPE-mediated oIPSC inhibition ([Figure 4e-f](#fig4){ref-type="fig"}) is indeed modulated by DOR activation, we pretreated the brain slices with naltrindole. This pretreatment occluded the DPDPE-mediated inhibition of oIPSCs ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Since PV-positive neurons reportedly contribute to feed-forward inhibition of MThal inputs to L5 pyramidal neurons in the ACC ([@bib10]), opioid modulation of oIPSCs of PV neurons onto L5 pyramidal neurons in the ACC was measured. *Pvalb-cre^+/-^;*Ai32^+/-^ mice ([@bib32]; [@bib17]) were used to express ChR2(H134R) in PV neurons, and oIPSCs were recorded from L5 pyramidal neurons ([Figure 5a](#fig5){ref-type="fig"}). The oIPSCs were potently inhibited by DPDPE but not DAMGO ([Figure 5b--c](#fig5){ref-type="fig"}; I~DAMGO~: 104.1 ± 6.1% of baseline, W(11) = 25, p=0.998; I~DPDPE~: 44.9 ± 5.7%, W(15) = 0, p\<0.001), suggesting that DORs were expressed on PV neurons in the ACC.

![DORs expressed on PV-positive interneurons suppress oIPSCs onto layer five pyramidal neurons.\
(**a**) Schematic of ChR2 expression and recording of oIPSCs of parvalbumin-positive interneurons (PV) to layer 5 (L5) pyramidal neurons (Pyr) in the ACC of *Pvalb-cre^+/-^;*Ai32^+/-^ mice. Blue: ChR2 expression and optical stimulation. (**b**) Example traces of oIPSCs during baseline (gray), application of DAMGO (1 µM, left panel, orange) and followed by CTAP (1 µM, left panel, black), or application of DPDPE (1 µM, right panel, teal) followed by naltrindole (0.3 µM, right panel, black). Blue bars: 1 ms of 470 nm light stimulation. (**c**) Summary data of PV interneurons to pyramidal neuron oIPSCs for all recording as in (**b**). Responses plotted as a percent of the baseline. DAMGO/CTAP: N = 5, n = 11, *SM* = 0.005, p=0.998; DPDPE: N = 8, n = 15; naltrindole: N = 5, n = 10, *SM* = 19.60, p\<0.001. (**d**) In-situ hybridization in wild-type mouse brain sections containing the ACC stained with probes against mRNA coding for *Oprd1* (*Oprd1*, left panel, green) and parvalbumin (*Pvalb*, middle panel, magenta) and overlaid with DAPI (right panel, cyan). (**e**) Immunohistochemistry of brain sections of the ACC from a *DOR-GFP* knockin mouse and stained with anti-GFP antibodies (left panel, green), and anti-parvalbumin antibodies (middle panel, magenta), and overlaid (right panel). (**f**) Venn diagram quantifying overlap of *Oprd1*-positive and *Pvalb*-positive (left panel, N = 2, n = 8), and DOR-GFP-positive and PV-positive cells in the mouse ACC (right panel, N = 2, n = 15). Skillings-Mack test followed by paired Wilcoxon signed-ranks test *post-hoc* analysis. \*, p\<0.05; \*\*, p\<0.01; \*\*\*p\<0.001. Mean ± standard error of the mean. *SM*: Skillings-Mack statistic.](elife-45146-fig5){#fig5}

Colocalization of DORs and parvalbumin was investigated at mRNA and protein levels ([Figure 5d--f](#fig5){ref-type="fig"}). Images of fluorescent RNA probes for endogenous DORs (*Oprd1*) and parvalbumin (*Pvalb*) revealed that the majority of *Pvalb*-positive cells were also *Oprd1*-positive ([Figure 5d,f](#fig5){ref-type="fig"}; 88.7 ± 1.4% of *Pvalb*-positive cells expressed detectable levels of *Oprd1*). A knockin mouse line expressing GFP-fused DORs ([@bib49]) was used to probe for the presence of DOR proteins in sections stained for parvalbumin proteins. Similarly, 95.0 ± 1.2% of parvalbumin protein-positive neurons expressed detectable levels of GFP ([Figure 5e--f](#fig5){ref-type="fig"}). Together, these data indicate that DORs are expressed on PV neurons, consistent with their role in inhibition of GABA release onto pyramidal neurons.

Delta-opioid agonists increase cortical excitability {#s2-5}
----------------------------------------------------

As DOR agonists selectively reduced feed-forward inhibition of the local PV neurons to pyramidal neurons in the ACC, activation of DORs was predicted to disinhibit ACC pyramidal neurons resulting in increased cortical excitability. Optical excitation of MThal terminals in the ACC evoked action potential (AP) firing in ACC L5 pyramidal neurons measured using a cell-attached recording configuration, recorded as action currents in voltage-clamp mode ([Figure 6a--c](#fig6){ref-type="fig"}). When APs were elicited in approximately 50% of the trials, activation of MORs by DAMGO decreased the fraction of trials that evoked action potentials (0.4 ± 0.1 fold change relative to baseline, paired t-test, p\<0.01), while activation of DORs by DPDPE led to a significant increase in AP firing probability (5 ± 3.1 fold change relative to baseline, paired t-test, p\<0.05). This was consistent with an inhibitory effect of MOR activation and a disinhibitory effect of DOR activation on pyramidal neuron firing rates ([Figure 6b--c](#fig6){ref-type="fig"}) with no significant effect on action potential latency ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Thus, DOR activation in the ACC resulted in disinhibition of the pyramidal neurons within the ACC, which led to increased cortical excitability.

![DOR activation results in increased cortical excitability.\
(**a**) Schematic of ChR2 expression and recording of optically-evoked action potentials (APs, recorded as action currents using voltage-clamp mode) using a loose cell-attached recording configuration. Blue: ChR2 expression and optical stimulation; magenta: outline of a parvalbumin-positive interneuron (PV). (**b**) Example traces of 50 trails from a single layer 5 (L5) pyramidal neuron (Pyr) in which APs were evoked by optical stimulation (blue bars) under baseline conditions, or in the presence of DAMGO (1 µM, orange), or DPDPE (1 µM, teal). (**c**) Summary data plotted on a log2 scale for action potential firing probability (P~AP~) in the presence of drugs (P~AP\ agonist~) relative to baseline (P~AP\ baseline~). Paired t-test; \*p≤0.05; \*\*p≤0.01. DAMGO: N = 3, n = 7; DPDPE: N = 5, n = 8.](elife-45146-fig6){#fig6}

Delta-opioid agonists facilitated thalamo-cortico-striatal signaling {#s2-6}
--------------------------------------------------------------------

The increased excitability upon DOR activation in L5 pyramidal neurons in the ACC was hypothesized to propagate to MSNs in the DMS via corticostriatal projections and result in increased glutamate release in the striatum. To test this hypothesis, AAV-ChR2(H134R) was injected into the MThal. Brain slices containing both the ACC and DMS were prepared ([Figure 7a](#fig7){ref-type="fig"}). Simultaneous recordings were made from L5 pyramidal neurons in the ACC (voltage recording) and MSNs in the DMS (current recording). Laser illumination was used to focally excite axons within the ACC or the DMS. When the ACC was illuminated, optogenetically stimulated MThal axons triggered action potentials in the L5 pyramidal neurons in the ACC, which then propagated to the DMS, and in turn, triggered a poly-synaptic oEPSCs in the MSNs ([Figure 7a](#fig7){ref-type="fig"}). In contrast, focal illumination in the DMS resulted in a short latency oEPSC in the MSNs in the DMS with no measurable responses in the L5 pyramidal neurons in the ACC. These results indicated that MThal-ACC-DMS circuits were preserved in this slice preparation. Long-latency poly-synaptic oEPSCs were also confirmed in MSNs in the DMS following widefield optical stimulation of the ACC ([Figure 7b](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1a](#fig7s1){ref-type="fig"}). Application of DPDPE increased the charge transfer of the poly-synaptic MThal→ACC→DMS oEPSCs ([Figure 7b--c](#fig7){ref-type="fig"}; Q~baseline~: 129.4 ± −46.2 fC; Q~DPDPE~: 344.7 ± 90.5 fC, W(7) = 2, p\<0.05). Amplitude changes of the poly-synaptic oEPSC in response to DPDPE, however did not reach statistical significance ([Figure 7---figure supplement 1b](#fig7s1){ref-type="fig"}; I~DPDPE~: 196.1 ± 41.0%, W(7) = 3, p=0.145). Taken together, the results indicate the presence of both MORs and DORs in the thalamo-cortico-striatal circuitry, where DORs primarily facilitated information flow in the indirect pathway from the MThal via the ACC to the DMS, while MORs suppressed information flow from the MThal directly to the DMS.

![DOR activation disinhibits thalamo-cortico-striatal circuits.\
(**a**) Schematic of ChR2 expression and dual recordings in layer 5 (L5) pyramidal neurons (Pyr) in the ACC and MSNs in the DMS. Blue: ChR2 expression and optical stimulation; magenta: outline of a parvalbumin-positive interneuron (PV). 470 nm light stimulation locations are shown as 1 and 2. (**b**) Example traces of current-clamp recording from a L5 pyramidal neuron in the ACC (upper panels), and voltage-clamp recording from a MSN in the DMS (lower panels) in response to light stimulations at location 1 (Str) and location 2 (ACC). (**c**) Example traces of poly-synaptic current evoked by optical stimulation of MThal terminals in the ACC (location 2) while recording from an MSN in the DMS during baseline (gray), and in presence of DPDPE (1 µm, teal). (**d**) Summary data of the charge transfer of poly-synaptic oEPSCs in the MSNs evoked by optical stimulation of location 2 in the ACC. Paired Wilcoxon signed-ranks test. \*p≤0.05; Gray: baseline; teal: DPDPE. (**e**) Summary schematic depicting a part of the affective and motivational pain circuit consisting of the MThal, ACC and DMS. Str: striatum.](elife-45146-fig7){#fig7}

Discussion {#s3}
==========

Despite the importance of the thalamo-cortico-striatal loop in affective pain and reward, the exact circuit mechanisms and how they are modulated by opioids are not fully understood. Previously, we described the mesoscopic anatomical connectivity between subregions within the thalamus and cortex, and the convergence of their axonal projections within the striatum ([@bib20]). Here, guided by such information, we used both anatomical and functional approaches to demonstrate the connectivity of the MThal, ACC and DMS. We found that projections from the MThal and ACC converged in the DMS, rather than the ventral striatum which has been well studied for reward and drug addiction. Further, we found different opioid receptors differentially affect projection-specific synapses ([Figure 7e](#fig7){ref-type="fig"}). Specifically, activation of MORs suppressed both MThal-ACC and MThal-DMS excitatory synapses, however, activation of DORs enhanced the excitatory input from the MThal to the pyramidal neurons in the ACC by disinhibiting local feed-forward inhibition mediated by PV interneurons in the ACC. This DOR-mediated disinhibition of MThal-ACC synapses has functional significance at the network level in that it facilitates information to flow from the MThal to the DMS via the ACC. Our results suggests that opioid effects on pain and reward are shaped by the relative selectivity of opioid drugs to the specific circuit components.

Convergence of thalamic and cortical inputs to the striatum {#s3-1}
-----------------------------------------------------------

Glutamate afferents from the midline cortical structures and medial thalamus converge to the DMS in the affective pain pathway. Here, we demonstrated that single MSNs in the DMS can receive inputs from both the midline cortex and medial thalamus. These results establish the anatomical basis for investigating convergence and integration within this circuit. Being able to detect convergence of MThal and ACC inputs at the level of the individual cell also paves the way for future studies of this circuit with single cell resolution at the population level.

Individual MThal neurons projects to both the ACC and DMS {#s3-2}
---------------------------------------------------------

Consistent with studies demonstrating cortical and striatal projections for midline thalamic neurons in rats ([@bib43]; [@bib29]), the simultaneous retrograde bead injections localized to the rostromedial ACC and DMS demonstrated double-labeling of individual neurons in the lateral MD and CL thalamus, suggesting that in mice single thalamic neurons can project to both the cortex and striatum. It should be acknowledged that the exact location of the retrograde bead labeled neurons relative to defined borders of the thalamic nuclei is not perfectly accurate since a small range of slices containing the MThal were fit to a single plane of the mouse atlas ([@bib13]) without correcting for irregularities such as brain slice angles. Furthermore, the diffusion of retrograde beads in brain tissue is limited such that each injection is relatively small and localized, thus, the number of colocalized neurons is not an absolute measure of the fraction of MD neurons projecting to both the ACC and DMS. Despite these constraints, the retrograde bead injections and retrograde viral labeling experiments both suggested the presence of a population of neurons in the MThal that project to both the ACC and DMS. We also confirmed that these collaterals originating from the MThal made functional en passant synapses in the DMS. Based on these tracing experiments and convergence of the cortical and thalamic inputs to the striatum experiments mentioned above, a circuit with a direct monosynaptic arm from the MThal to the DMS, and an indirect poly-synaptic arm from the MThal via ACC to the DMS is described.

Opioid modulation of the thalamo-cortico-striatal circuitry {#s3-3}
-----------------------------------------------------------

The MOR agonist DAMGO had a strong inhibitory effect on the MThal inputs to the DMS, whereas neither DAMGO nor the DOR agonist DPDPE had a significant effect on the ACC inputs to the DMS. These results indicate that the midline thalamostriatal pathway stands as a major source of opioid-regulated glutamate inputs to the DMS, and that MOR agonists alter the relative influence of cortical and thalamic inputs on DMS excitability. The MThal inputs to the ACC were also inhibited by MOR agonists. Given the extensive MOR-sensitive axonal projections from the MThal to the ACC, it is possible that the analgesic and rewarding effect of morphine injection into the ACC is due in part to inhibition of thalamic glutamate inputs to the ACC ([@bib40]). Together, MOR activation may selectively suppress information from MThal to the striatum either directly or indirectly, but may leave intact other information that is also going through the ACC to the striatum. This may contribute to the selective analgesic and rewarding effect of morphine without affecting other cognitive functions.

There are two major subtypes of MSNs in the striatum, dopamine receptor 1 (D1)-positive and dopamine receptor 2 (D2)-positive MSNs each making up \~50% of total MSNs. While we have not observed any bi-modal distribution or obvious heterogeneity in MSN responses, it will be interesting to investigate the cell type-specific and input-specific opioid sensitivity in this circuit in the future.

Opposing effects of opioid subtypes on circuitry modulation {#s3-4}
-----------------------------------------------------------

Although all opioid receptors couple to the inhibitory G~i~ pathway, their effect on the circuit can be distinct. In this study, the lack of strong inhibition of DORs on glutamate transmission in the corticostriatal projections together with the potent DOR inhibition of GABA release from PV interneurons to pyramidal neurons in the ACC allows for DORs to function in a disinhibitory manner. DOR activation effectively leads to hyper-excitable ACC circuits, while MOR activation functions in an inhibitory manner, dampening glutamate release in the thalamo-cortico-striatal circuit. These results complement a previous study in which DOR activation resulted in increased activity in the rat insular cortex following dental pulp stimulation, while MOR activation decreased the insular cortex activity ([@bib59]). A follow-up study found that inhibitory transmission from fast-spiking interneurons to pyramidal neurons was inhibited by DOR activation ([@bib60]). The current results extend these findings to the mouse ACC and identify that specifically, PV interneurons are a target of DOR inhibition.

While PV interneurons have been suggested to selectively mediate feed-forward inhibition of thalamocortical transmission in the ACC, it is important to note that the current findings do not rule out potential influence of opioids on other interneuron populations. In fact, immunohistochemical and in situ hybridization data presented here suggest that DOR expression is not restricted to PV interneurons, as only approximately 20% of DOR-positive neurons were parvalbumin-positive ([Figure 4e](#fig4){ref-type="fig"}). Furthermore, certain neurons in the ACC have been shown to express MORs ([@bib51]; [@bib54]; [@bib56]), suggesting that there are additional opioid-sensitive neurons within the local ACC circuits.

It has recently been shown that MOR agonists can modestly inhibit insular-striatal glutamate transmission ([@bib36]). In this study ACC-striatal transmission was relatively insensitive to MOR and DOR agonists, while PFC-striatal transmission appeared marginally sensitive to the DOR agonist DPDPE. Thus, there may be heterogeneity in the opioid sensitivity of cortical projections to the striatum. The current results also suggest that MORs and DORs are positioned to serve opposing functions in regulating affective pain circuitry and reward and motivated behaviors. In addition, an important aspect is how endogenous opioid receptor ligands modulate this circuit. Future technological development might allow the investigation of endogenous ligand release and their effects on specific components of the thalamo-cortico-striatal loop, as outlined in this work.

The MD, ACC, and striatum have been demonstrated to play roles in pain- and reward-related behaviors ([@bib25]; [@bib30]; [@bib31]; [@bib16]; [@bib38]). Therefore, some aspects of the analgesic and rewarding/addictive effects of opioids may arise from modulation within the poly-synaptic circuits between the MThal, ACC and striatum described here. Increased ACC activity is associated with increased affective pain intensity and decreased ACC activity is associated with analgesia ([@bib23]). The current results suggest that drugs acting in the ACC at either MOR or DOR have the potential to modulate this circuitry. These data also suggest that commonly prescribed and abused opioids, which primarily act through MOR, could alter the relative influences of glutamate inputs to the striatum in addition to their postsynaptic effects on striatal MSNs.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                         Designation                                                           Source or\                                        Identifiers                                                                               Additional\
  (species) or\                                                                                                               reference                                                                                                                                   information
  resource                                                                                                                                                                                                                                                                
  ----------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------- ----------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
  Strain, strain background (*M. musculus, C57BL/6J*)   wildtype                                                              Jackson Laboratories                              Stock \# 000664 RRID: [IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)   

  Genetic reagent (M. musculus)                         Ai32 (B6;129S-Gt(*ROSA*)*26Sortm32*(*CAG-COP4\*H134R/EYFP*)*Hze*/J)   Jackson Laboratories                              Stock \# 012569 RRID: [IMSR_JAX:012569](https://scicrunch.org/resolver/IMSR_JAX:012569)   PMID: [22446880](https://www.ncbi.nlm.nih.gov/pubmed/22446880)

  Genetic reagent (M. musculus)                         Ai9 (B6.Cg-*Gt*(*ROSA*)*26Sor tm9*(*CAG-TdTomato*)*Hze*/J)            Jackson Laboratories                              Stock \# 007909 RRID: [IMSR_JAX:007909](https://scicrunch.org/resolver/IMSR_JAX:007909)   PMID: [20023653](https://www.ncbi.nlm.nih.gov/pubmed/20023653)

  Genetic reagent (M. musculus)                         Pvalb-IRES-Cre (B6.129P2-*Pvalbtm1(cre)Arbr*/J)                       Jackson Laboratories                              Stock \# 008069 RRID: [IMSR_JAX:007909](https://scicrunch.org/resolver/IMSR_JAX:007909)   PMID: [15836427](https://www.ncbi.nlm.nih.gov/pubmed/15836427)

  Genetic reagent (M. musculus)                         Slc17a6-IRES-Cre (B6.*Slc17a6tm2(cre)Lowl*/J)                         Jackson Laboratories                              Stock \# 016963 RRID: [IMSR_JAX:016963](https://scicrunch.org/resolver/IMSR_JAX:016963)   PMID: [21745644](https://www.ncbi.nlm.nih.gov/pubmed/21745644)

  Genetic reagent (*Dependoparvovirus*)                 AAV2-syn-hChR2 (H134R)-EYFP                                           UNC virus vector core                             NA                                                                                        

  Genetic reagent (*Dependoparvovirus*)                 AAV2/1-CAG-hChR2 (H134R)-TdTomato                                     UPenn Vector Core                                 Addgene plasmid \# 28017                                                                  PMID: [21982373](https://www.ncbi.nlm.nih.gov/pubmed/21982373)

  Genetic reagent (*Dependoparvovirus*)                 AAV2-syn-ChrimsonR-TdTomato ([@bib26])                                UNC virus vector core                             NA                                                                                        PMID: [24509633](https://www.ncbi.nlm.nih.gov/pubmed/24509633)

  Genetic reagent (*Dependoparvovirus*)                 AAV2-syn-CsChR-GFP ([@bib26])                                         UNC virus vector core                             NA                                                                                        PMID: [24509633](https://www.ncbi.nlm.nih.gov/pubmed/24509633)

  Genetic reagent (*Dependoparvovirus*)                 AAVrg-pmSyn1-EBFP-cre ([@bib32]; [@bib52])                            Addgene                                           Cat\# 51507                                                                               PMID: [25741722](https://www.ncbi.nlm.nih.gov/pubmed/25741722), [27720486](https://www.ncbi.nlm.nih.gov/pubmed/27720486)

  Genetic reagent (*Dependoparvovirus*)                 AAV2-FLEX-CAG-TdTomato                                                UNC virus vector core                             NA                                                                                        

  Genetic reagent (*Dependoparvovirus*)                 AAV2-SSpEMBOL-Chicken-beta-actin (CBA)-GFP                            UNC virus vector core                             NA                                                                                        

  Genetic reagent (*Dependoparvovirus*)                 AAV1-CAG-hChR2 (H134R)-TdTomato                                       UPenn Vector Core                                 Addgene plasmid \# 28017                                                                  PMID: [21982373](https://www.ncbi.nlm.nih.gov/pubmed/21982373)

  Genetic reagent (*Dependoparvovirus*)                 AAV2-DIO-EF1alpha-ChR2 (H134R)-EYFP                                   UNC virus vector core                             NA                                                                                        

  Antibody                                              Living Colors DsRed Polyclonal Anibody                                Takara Bio/Clontech                               Cat\# 632496 RRID: [AB_10013483](https://scicrunch.org/resolver/AB_10013483)              dilution: 1:500

  Antibody                                              Anti-GFP chicken Polyclonal IgY fraction                              Thermo Fisher                                     Cat\# A10262 RRID: [AB_2534023](https://scicrunch.org/resolver/AB_2534023)                dilution: 1:500

  Antibody                                              Alexa Fluor 488 goat anti-chicken Polyclonal IgG                      Thermo Fisher                                     Cat\# A11039 RRID: [AB_2534096](https://scicrunch.org/resolver/AB_2534096)                dilution: 1:750

  Antibody                                              Alexa Fluor 594 goat anti-rabbit Polyclonal IgG (H + L)               Thermo Fisher                                     Cat\# A11012 RRID: [AB_2534079](https://scicrunch.org/resolver/AB_2534079)                dilution: 1:750

  Antibody                                              Anti-parvalbumin goat Polyclonal                                      Swant                                             Cat\# PVG 214 RRID: [AB_10000345](https://scicrunch.org/resolver/AB_10000345)             dilution: 1:1000

  Antibody                                              Anit-GFP chicken Polyclonal                                           Abcam                                             Cat\# ab13970 RRID: [AB_300798](https://scicrunch.org/resolver/AB_300798)                 dilution: 1:1000

  Chemical compound, drug                               Mecamylamine                                                          R and D Systems/Tocris                            Cat\# 2843                                                                                

  Chemical compound, drug                               Scopolamine                                                           Sigma Aldrich                                     Cat\# S1013                                                                               

  Chemical compound, drug                               SR95531                                                               Hello Bio                                         Cat\# HB0901                                                                              

  Chemical compound, drug                               Picrotoxin                                                            Hello Bio                                         Cat\# HB0506                                                                              

  Chemical compound, drug                               \[Met^5^\]-enkephalin                                                 Sigma Aldrich                                     Cat\# M6638                                                                               

  Chemical compound, drug                               DAMGO                                                                 Sigma Aldrich                                     Cat\# E7384                                                                               

  Chemical compound, drug                               CTAP                                                                  R and D Systems/Tocris                            Cat\# 1560                                                                                

  Chemical compound, drug                               Naloxone                                                              Abcam                                             Cat\# ab120074                                                                            

  Chemical compound, drug                               DPDPE                                                                 Sigma Aldrich                                     Cat\# E-3888                                                                              

  Chemical compound, drug                               Naltrindole                                                           Sigma Aldrich                                     Cat\# N-115                                                                               

  Chemical compound, drug                               ICI 174,864                                                           R and D Systems/Tocris                            Cat\# 0820                                                                                

  Chemical compound, drug                               MK801                                                                 Hello Bio                                         Cat\# HB0004                                                                              

  Chemical compound, drug                               CPP                                                                   R and D Systems/Tocris                            Cat\# 0173                                                                                

  Chemical compound, drug                               CGP 55845                                                             R and D Systems/Tocris                            Cat\# 1248                                                                                

  Chemical compound, drug                               Bestatin                                                              Sigma Aldrich                                     Cat\# B8385                                                                               

  Chemical compound, drug                               Thiorphan                                                             Sigma Aldrich                                     Cat\# T6031                                                                               

  Chemical compound, drug                               MPEP                                                                  R and D Systems/Tocris                            Cat\# 1212                                                                                

  Chemical compound, drug                               Red Retrobeads IX                                                     Lumafluor Inc                                     Cat\# R180                                                                                

  Chemical compound, drug                               Green Retrobeads IX                                                   Lumafluor Inc                                     Cat\# R180                                                                                

  Chemical compound, drug                               DNQX                                                                  Sigma Aldrich                                     Cat\# D0540                                                                               

  Chemical compound, drug                               QX314                                                                 R and D Systems/Tocris                            Cat\# 2313                                                                                

  Commercial assay, kit                                 RNAscope Multiplex Fluorescent Assay                                  Advanced Cell Diagnostics                         Cat\# 320850                                                                              

  Commercial assay, kit                                 RNAscope Probe- Mm-Oprd1                                              Advanced Cell Diagnostics                         Cat\# 427371                                                                              

  Commercial assay, kit                                 RNAscope Probe- Mm-Pvalb-C2                                           Advanced Cell Diagnostics                         Cat\# 421931-C2                                                                           

  Software, algorithm                                   FIJI 1.49b                                                            Wayne Rasband, NIH                                PMID: [22743772](https://www.ncbi.nlm.nih.gov/pubmed/22743772)                            

  Software, algorithm                                   AxoGraph 1.4.4                                                        Axograph                                                                                                                                    

  Software, algorithm                                   Microsoft Excel 2011                                                  Microsoft Corp.                                                                                                                             

  Software, algorithm                                   Illustrator CS5                                                       Adobe Systems                                                                                                                               

  Software, algorithm                                   Photoshop CS5                                                         Adobe Systems                                                                                                                               

  Software, algorithm                                   Prism 6                                                               GraphPad                                                                                                                                    

  Software, algorithm                                   Imaris                                                                Bitplane                                                                                                                                    

  Software, algorithm                                   Zen                                                                   Zeiss                                                                                                                                       

  Software, algorithm                                   Chart 5                                                               AD Instruments                                                                                                                              

  Software, algorithm                                   Matlab r2007b and r2018a                                              Mathworks                                                                                                                                   

  Software, algorithm                                   R (3.5.0)                                                             R Development Core Team                                                                                                                     

  Software, algorithm                                   Ephus                                                                 Vidrio Technologies, LLC                                                                                                                    

  Software, algorithm                                   Custom data analysis software                                         <https://gitlab.com/maolab/opi_syn_circuit.git>                                                                                             Data and analysis scripts related to quantification in manuscript and rebuttal
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All procedures were approved by Oregon Health and Science University Institutional Animal Care and Use Committee (IACUC) under protocol IP00000955, and Institutional Biosafety Committee under protocol IBC-10--40. Mice of both sexes were used in all experiments and were five to eight weeks of age at the time of brain slice preparation. Stereotaxic injections were performed on three- to five-week-old mice. Mice were housed in group housing, given free access to food and water, and maintained on a 12 hr light/dark cycle. List of resources can be found in Key resources table. The software, and data sets generated and analyzed during the current study are available upon request to the corresponding authors.

Viral injection {#s4-1}
---------------

Stereotaxic injections were performed as previously described ([@bib19]; [@bib4]) to deliver recombinant adeno-associated virus (AAV) to express channelrhodopsin variants. Briefly, mice were deeply anesthetized with isofluorane and head fixed into a stereotaxic alignment system (Kopf Instruments, Tujunga, CA, with custom modifications). Small holes were drilled through the skull above the desired injection site and a glass pipette filled with virus was lowered through the hole to the desired injection depth. A small volume (20--40 nl) of virus was injected (WTB and KAE: Nanoject II, Drummond Scientific, Broomall, PA; BCJ: custom-built injector based on a MO-10, Narishige, Amityville, NY). Injection coordinates are listed below in mm for medial/lateral (M/L), anterior/posterior from bregma (A/P), and dorsal/ventral from the top of the skull directly over the target area. Target areas included (in mm): medial thalamus (MThal): M/L: 0.55, A/P: −1.2, D/V: 3.6; anteromedial thalamus (AMThal): M/L: 0.55, A/P: −0.4, D/V: 3.4; anterior cingulate cortex (ACC): M/L: 0.4, A/P: 0.7, D/V:1.6; prefrontal cortex (PFC): M/L: 0.45, A/P: 1.75, D/V: 1.6, dorsomedial striatum (DMS); M/L: 1.5; A/P: 0.55, D/V: 3.6 to 3.3.

Brain slice electrophysiology {#s4-2}
-----------------------------

Two to three weeks after viral injection, acute brain slices were prepared. Two different slicing protocols were used depending on whether recordings were being obtained from the striatum or ACC. Recordings were made from both slicing solutions and similar results were obtained.

For striatal recordings, coronal brain slices (250--300 µm) were prepared from either ice-cold or room temperature Krebs buffer containing (in mM): 125 NaCl, 21.4 NaHCO~3~, 11.1 D-glucose, 2.5 KCl, 1.2 MgCl~2~, 2.4 CaCl~2~, 1.2 NaH~2~PO~4~,\~305 mOsm, supplemented with 5 µM MK-801 and saturated with 95% O~2~/5% CO~2~. Slices were incubated in oxygenated Krebs buffer supplemented with 10 µM MK-801 for 30 min at 33°C and then maintained in a holding chamber at 22--24°C.

For cortical recordings, coronal brain slices (300--350 µm) were prepared in a carbogen saturated choline-based cutting solution containing (in mM): 110 choline chloride, 25 NaHCO~3~, 25 D-glucose, 2.5 KCl, 7 MgCl~2~, 0.5 CaCl~2~, 1.25 NaH~2~PO~4~, 11.5 sodium ascorbate, and three sodium pyruvate,\~315 mOsm. Slices were incubated in oxygenated artificial cerebrospinal fluid (aCSF) containing (in mM): 127 NaCl, 25 NaHCO~3~, 25 D-glucose, 2.5 KCl, 1 MgCl~2~, 2 CaCl~2~, and 1.25 NaH~2~PO~4~ for 30 min at 33--34°C and then maintained in a holding chamber at 22--24°C.

Two experimenters (WTB and BCJ) using two rigs performed whole-cell recordings; experimenters' initials below note differences between experimental setups. There were no differences in results between experimenters so all data were pooled. Recordings were obtained at near-physiological temperature (32--34°C) from slices superfused with (BCJ) oxygenated aCSF supplemented with (in µM, see Key resources table): 10 GABA~B~-receptor antagonist CGP 52432, 10 GABA~A~-receptor antagonist SR-95531, 10 nicotinic acetylcholine receptor mecamylamine, 10 muscarinic acetylcholine receptor antagonist scopolamine, 0.3 metabotropic glutamate receptor five antagonist MPEP, 5 NMDA receptor antagonist CPP, or (WTB) oxygenated Krebs supplemented with (in µM, see Key resources table): 0.2 GABA~B~-receptor antagonist CGP 55845, 10 GABA~A~-receptor antagonist picrotoxin, one mecamylamine, 0.1 muscarinic acetylcholine receptor antagonist atropine or 0.1 scopolamine and 0.3 MPEP, preincubated in 5 MK-801.

Electrophysiology data acquisition {#s4-3}
----------------------------------

Borosilicate pipettes (2.8--4 MΩ; Sutter Instruments, Novato, CA) were filled with potassium gluconate-based internal solution (in mM: 110 potassium gluconate, 10 KCl, 15 NaCl, 1.5 MgCl~2~, 10 HEPES, 1 EGTA, 2 Na~2~ATP, 0.3 Na~2~GTP, 7.8 phosphocreatine; pH 7.35--7.40;\~280 mOsm) for striatal recordings. Putative MSNs were identified by their morphology and stereotypic physiological properties. Evoked excitatory postsynaptic currents (EPSCs) were recorded in whole-cell voltage-clamp mode at −75 mV holding potential.

To facilitate measurement of both GABA~A~- and AMPA-mediated currents, cortical recordings were obtained using a low-chloride cesium gluconate solution (in mM: 135 Glucaronic acid, 1 EGTA, 1.5 MgCl~2~, 10 HEPES, 2 Na2ATP, 0.3 GTP, 7.8 Na~2~ Phosphocreatine, titrated to pH 7.35--7.4 with CsOH,\~280 mOsm and 3 QX314 chloride added fresh before experiment) in the absence of GABA~A~ antagonists. Sodium and chloride reversal-potentials were empirically determined by recording spontaneous EPSCs/IPSCs, isolated by presence of GABAergic or glutamatergic antagonists, respectively, under a range of holding potentials (−90 to 40 mV with 5 mV increments each for 1 min recording duration). oEPSC and oIPSC were recorded at −55 and 5 mV, respectively.

Whole-cell voltage and current clamp recordings were collected by WTB using an Axopatch 200A amplifier (Molecular Devices, San Jose, CA), digitized at 20 kHz (Instrutech ITC-16, New York, NY), and recorded (Axograph X software), and by BCJ using an Multiclamp 700B amplifier (Molecular Devices) digitized at 10 kHz and recorded with *Ephus* software ([www.ephus.org](http://www.ephus.org)). Optically evoked currents were elicited by LED illumination through the microscope objective (WTB and BCJ, Olympus, Tokyo, Japan, BX51W with 60X, 1.0 NA water immersion objective, except for polysynaptic circuit activation which utilized a 20X, 0.5 NA water immersion objective), or by laser illumination (473 nm Crystal Laser, Reno, NV) through the microscope objective (BCJ, details see [@bib34]) Neuron). In brief, laser beam position was controlled by galvanometer scanners (Cambridge Technology, Bedford, MA). Beam was passed through an air objective (4 x, 0.16 NA, UPlanApo, Olympus, beam diameter \~8--16 µm). Timing and light power of the laser stimulation was controlled by a TTL-controlled shutter (Uniblitz, Rochester, NY) with typical dwell time 1 ms (up to 5 ms for polysynaptic and loose cell-attached experiments in [Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}), and a circular gradient neutral-density filter of 0.04--1.5 optical density (Edmund Optics, Barrington, NJ) set to yield typical 3--5 mW power after objective, respectively. For LED stimulation a TTL-controlled LED driver and 470 nm LED (Thorlabs, Newton, NJ) were used to illuminate the slice directly over the recorded cell generally with \~1 mW of power for 0.5 ms or 1 ms, although power was increased or decreased if evoked currents were unusually weak or strong, respectively. For two-wavelength optical excitation, single flashes of 470 nm (one msec,\<0.5 mW) and 625 nm LEDs (3 ms, 1.4 mW, Thorlabs) were used.

Electrophysiology data analysis {#s4-4}
-------------------------------

Data collected by WTB were analyzed either in Axograph or Matlab, data collected by BCJ in *Ephus* were analyzed in Matlab. Pooled data were processed in Matlab and R. All collected data were analyzed using the same protocols. Peak current amplitude was calculated relative to mean current during 50 ms baseline prior to the stimulus. In three cases the recorded oIPSCs (recorded as positive current) was completely blocked in the presences of DAMGO, yielding a small negative current deflection (residual EPSC-mediated sodium current as a result of imperfect voltage-clamp at the estimated sodium-reversal potential). To calculate agonist effects on the oIPSCs relative to baseline recordings the small negative currents were substituted with a positive current value (0.00001 pA). Signal latencies were calculated between stimulation and 10% of peak current for oEPSCs or peak of action potentials. Charge transfer was calculated by integrating recorded current during a defined time window following photostimulation, as described below, and was corrected by baseline charge transfer during a time window measured immediately prior to stimulation. In [Figure 4---figure supplement 2a](#fig4s2){ref-type="fig"} large portion of 'non-responding' cells were observed in experiments from 'tail' injected mice (hippocampus +retrosplenial cortex). In order to determine the charge transfer in an unbiased way, we first determined the averaged onset, rise, and decay time of monosynaptic inputs to the recorded cells (thalamic and cortical inputs to the MSNs, thalamic inputs to the L2/3 or L5 pyramidal neurons), and determined the integration time window (averaged rise +decay time) and the time position relative to stimulation (averaged onset time) for individual cell types. These cell type-specific integration time windows and positions allowed us to determine the charge transfer in an unbiased way in both responding and non-responding cells. Charge transfer of polysynaptic currents ([Figure 7c](#fig7){ref-type="fig"}) were calculated as integrated current between onset and decay time window, both defined as 10% of peak current.

Retrograde bead injection and tissue processing {#s4-5}
-----------------------------------------------

Red and green retrobeads (Lumafluor, Durham, NC) were injected similar to viral injections described above with the exception that 100 and 200 nl of retrobeads were injected into the cortex and striatum, respectively. Five days post-injection, mice were transcardially perfused with phosphate-buffered saline (PBS) followed by 4% formaldehyde in PBS. Brains were dissected and stored overnight in 4% formaldehyde in PBS. Sections containing injection sites were sliced at 100 µm thickness, and sections containing the thalamus were sliced at 50 µm thickness and stained with DAPI (300 nM in PBS) to label nuclei.

Fluorescent imaging and analysis for retrograde bead labeling {#s4-6}
-------------------------------------------------------------

Thalamic sections containing red and green retrobeads were imaged at 20x magnification using three laser lines (405, 488 and 561 nm) on a Yokogawa spinning disk confocal microscope (Carl Zeiss, Oberkochen, Germany). A Z-stack series was acquired with a 0.44 µm optical section thickness, and for each image 3 x 3 tiles with 15% overlap were applied. Laser power and exposure times were identical for all images. Retrobead-labeled cells were manually counted on Imaris 9.0 software (Bitplane) and each slice was recounted twice with consistent exposure settings to generate an average. A cell was counted if at least two punctate fluorescent spots were orthogonally detected directly adjacent to DAPI-labeled nuclei. Colocalization of dual-color spots was quantified using a built-in Imaris function with criteria that red and green-labeled spots must be spaced no more than 8 µm apart.

Subsequent imaging alignment was performed according to the mouse brain atlas ([@bib13]), and aligned using Adobe Photoshop and Illustrator. Sections containing the mediodorsal thalamus were aligned to the corresponding mouse brain atlas section (Figure 45, [@bib13]) using the hippocampus, habenula, and third ventricle as landmarks; and red, green, and red/green colocalized cells were hand-traced onto the aligned atlas figure. Injection sites were imaged on a brightfield epifluorescent macroscope (Olympus MVX10) using identical settings, and uniform thresholds were established using fluorescent values from the top 90% brightest pixels (ImageJ). The outline of each injection site was aligned to a representative mouse brain atlas section to view the average injection area (for the ACC, Figure 22 and for the DMS, Figure 28 of the Franklin and Paxinos atlas, second edition; [@bib13]).

Retrograde viral cell labeling {#s4-7}
------------------------------

A 60 nl viral mix containing a 3:1 ratio of rAAV2-retro-Cre (AAVrg-pmSyn1-EBFP-cre, Addgene) and AAV2-GFP (UNC viral core) was injected into the ACC, and a 90 nl injection of AAV2-FLEX-TdTomato (UNC viral core) was injected in the ipsilateral MThal. Three weeks post-injection, mice were transcardially perfused as described above and brains were sectioned 50 µm thick in PBS the following day.

Immunohistochemistry and imaging for retrograde viral cell label {#s4-8}
----------------------------------------------------------------

All incubation steps were performed on a shaker and at room temperature unless otherwise stated. Immediately post-slicing, sections were washed with PBS, and then permeabilized for 20 min with 1% Triton X-100 in PBS. Sections were subsequently incubated for 1 hr in blocking solution containing PBS with 1% triton X-100% and 0.5% fish skin gelatin (FSG). Rabbit anti-DsRed (Clontech, Mountain View, CA) and chicken anti-GFP (Invitrogen, Carlsbad, CA) primary antibodies diluted 1:500 in the blocking solution were incubated at 4°C overnight. Secondary antibodies were diluted 1:750 and incubated for 2 hr in the blocking solution. Sections were stained with 300 nM DAPI for 30 min to label nuclei, then mounted on microscope slides and embedded in an aqueous-based mounting solution (Fluoromount, Sigma Aldrich, Saint Louis MO). Imaging conditions are similar to retrograde bead labeling experiments. Red and green axons in the DMS were imaged at 63x using a Zeiss LSM 880 with Airyscan on a single tile with 0.44 µm optical section thickness.

PV/DOR In Situ hybridization {#s4-9}
----------------------------

Advanced Cell Diagnostics RNAscope Technology (ACD Bioscience, Newark, CA) was used to quantify cells containing *Oprd1* and *Pvalb* mRNA. Briefly, wild-type mice (five to eight weeks old) were deeply anesthetized with ketamine-xylazine and perfused transcardially with 0.1 M PBS, followed by 4% formaldehyde solution in phosphate buffer (PB). Brain was dissected, cryoprotected in 30% sucrose overnight and then frozen in OCT. Frozen tissue was sectioned at 20 μm, transferred onto Superfrost Plus slides and kept at −80°C. Tissue was thawed from −80°C, washed with PBS at room temperature and subsequently processed according to the manufacturer\'s protocol. We first pretreated the tissue with solutions from the pretreatment kit to permeabilize the tissue, and then incubated with protease for 30 min and the hybridization probes for another 2 hr at 40°C ([@bib56]).

PV/DOR Immunohistochemistry {#s4-10}
---------------------------

A previously described immunostaining protocol was employed ([@bib3]; [@bib50]). Briefly, five to eight week-old mice were deeply anesthetized with ketamine-xylazine and perfused transcardially with 0.1 M PBS, followed by 4% formaldehyde solution in 0.1 M PB. The brain was dissected, post-fixed for 4 hr at 4°C, and cryoprotected overnight in 30% sucrose in PBS. Frozen brain tissue was then sectioned at 40 µm and incubated with a 5% NDST blocking solution (0.3% Triton X-100 solution in 0.1 M PBS plus with 5% normal donkey serum) for at least 1 hr. The primary antibody was diluted in the same solution, and incubated with brain sections overnight at 4°C. After washing the primary antibody three times for 5 min with 0.3% Triton X-100 solution in 0.1 M PBS, sections were incubated with secondary antibody solution in 1% NDST solution at room temperature for 2 hr. Sections were then mounted on microscope slides with Fluoromount (Southern Biotech, Birmingham, AL) after washing with PB for three times for 5 min. Images were acquired with a confocal microscope (Leica DM2500, Wetzlar, Germany). The following primary antibodies were used: anti-GFP: Abcam (chicken; 1:1,000); anti-Parvalbumin: Swant (goat; 1:1,000).

Quantification and statistical analysis {#s4-11}
---------------------------------------

For electrophysiology experiments, to avoid observer-bias all data was quantified using automated custom-written analysis software ([@bib24]) followed by manual confirmation. For in-situ hybridization experiments, signals were manually counted, and cells displaying five or more labeled dots in their cytoplasm were considered positive. All experiments involving conditions (baseline, agonist, antagonist) were first tested with a Skillings-Mack test for significant changes in any of the conditions. Only when a significant change was reported (α = 0.05), three Wilcoxon signed-rank tests between combination of conditions was performed, unless stated otherwise. The Skillings-mack test is a non-parametric test, which allows for missing data points (unbalanced design). Dual-channelrhodopsin experiments ([Figure 1D](#fig1){ref-type="fig"} and Figure 1---figure supplement 1h S2H) required a linear mixed model (LMM) since a 3-way ANOVA could not be performed due to unbalanced design. LMM accounted for correlation of measurement within individual cells (random effects). The fixed effects in the LMM were opioid type (mu vs. delta), source (MThal vs. ACC/PFC), condition (baseline vs. agonist vs. antagonist), as well as all interactions referred in the text as two-way (opioid type x source, opioid type x condition, source x condition) and three-way (opioid type x source x condition). Due to the paucity of observations (n = 7/8) and high number of fixed effects, we relaxed the type I error for the LMM to detect significant trends in interactions (α = 0.15). *Post-hoc* analysis of *a priori* hypothesis for specific comparisons were performed using linear combinations based on the LMM (α = 0.05). All source data and related custom software for quantification and statistical analysis are available at GitLab ([@bib24]; copy archived at <https://github.com/elifesciences-publications/opi_syn_circuit>). The number of experiments performed with independent mice (N) and recorded neurons or counted slices, in case of in situ hybridization or immunohistochemistry, (n) is indicated in the legends. Error bars represent standard error of the mean.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Synapse-specific Opioid Modulation of Thalamo-cortico-striatal Circuits\" for consideration by *eLife*. Your article has been reviewed by Ronald Calabrese as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Christopher Ford (Reviewer \#1); Carlos Paladini (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This study examines how opioid receptors modulate synaptic transmission in thalamo-cortico-striatal circuits. Opioids strongly regulates these circuits and determining exactly where in these circuits these receptors act to gate thalamo-cortical activity into the striatum is an important question. The authors used optogenetics (two color ChR2 chrimson/chronos) in brain slices to thoroughly identify where and how mu and δ opioid receptor alter circuit activity in these regions. They show that MORs but not DORs strongly inhibit medial thalamic glutamatergic inputs to the DMS and ACC, and that a proportion of mThal neurons that project to the ACC also project to the DMS. Within this circuit DORs are expressed primarily on PV interneurons in the ACC where they function to regulate feed-forward inhibition into the ACC. Finally, they show that MORs inhibit thalamo-cortical-striatal circuits while DORs alternatively disinhibit these circuits. This work advances our understanding of how opioids mechanistically can alter circuit activity that likely underlies the affective-motivational aspects of pain processing.

Essential revisions:

The following points must be addressed before final acceptance of the manuscript. Most of these concerns can be addressed with additional analysis, modifications of the figures and extension of the Discussion section. For your understanding of these essential revisions, the full reviews are appended below.

1\) In Figure 3E,F, it is unclear what proportion of MSNs exhibited an EPSC when AAV2-retro-Cre was injected into the AAC and AAV-DiO-ChR2 was injected into the MThal. Further describing the proportion of cells in the DMS exhibited EPSCs would help show the distribution of cells that receive input from mThal cells that also project to the ACC. A scatter plot of the responders/non-responders of MSNs that exhibited EPSCs would be informative.

2\) There is concern about the lack of reversal (due to no application of antagonist) or application of antagonist that does not reverse the opioid inhibition of the synaptic response/firing of the cell. In several experiments neurons are included in the analysis where the opioid inhibition is not reversed by the antagonist (e.g. Figure 4C,F; Figure 4---figure supplement 1C,F, Figure 5C). There also appear to be cells that have a data point for the agonist but without a connected data point for the antagonist. For example, Figure 4---figure supplement 1, Figure 4C,F, Figure 5. Of particular concern is the data shown in figure 4f which is pivotal to the interpretation of the data presented in this study. The effect of DPDPE on the IPSC seems very variable. In some cells the agonist inhibited the response and this was sometimes reversed, sometimes no antagonist response is shown (for largest inhibition) and in some cases the antagonist produced a large overshoot in the size of the synaptic current. There only appears to be one cell where δ receptor activation reduces the size of the IPSC and this is reversed to baseline by the antagonist. How could these changes in synaptic responses be due to activation of the relevant opioid receptor if they were not reversed by the relevant antagonist? If there is a biological basis for it, rather than experimental, it would be interesting to see it discussed.

3\) The authors suggest that overall activation of the striatum will determine whether the person experiences the affective aspect of pain (Introduction). Is there evidence that activation of the striatum, regardless of whether this comes from the thalamus or cortex, is aversive? Or do the different inputs to the striatum result in a different experience of the aversive component of pain?

4\) It is surprising that, given the substantial circuit differences from D1 and D2 spiny projection neuron activation, that D1 and D2 SPNs were not identified. Although the differential effect of MOR agonist alleviates this concern, it is nonetheless preferable to have an independent measure that each laser activates distinct pathways. When activating the 470 laser and the 625 laser simultaneously, the currents should sum linearly if they are from distinct inputs.

5\) Does Figure 6B show action potentials? These must be escaped action currents. Nevertheless, they appear to have half-widths of 3 ms. Using escaped action currents as a measure of firing rate may be affected by the \"voltage command\" even when not broken in to the whole-cell mode.

6\) Do the specific MThal inputs to ACC synapse on the ACC projections to DMS?

7\) Although different opioids may have differing effects, it is difficult to discern what the endogenous effect of opioids may be on the circuit. MOR activation on MThal to ACC pyramidal pathway causes a decrease in EPSC amplitude and a decrease in IPSC amplitude. Meanwhile, DOR activation causes a decrease in IPSC amplitude in ACC pyramidal neurons. What is the net effect on firing?

*Reviewer \#1:*

In the present manuscript Birdsong and Jongloets et al., examine how opioid receptors modulate synaptic transmission in thalamo-cortico-striatal circuits. Over a series of careful experiments, the authors use optogenetics in brain slices to thoroughly identify where and how mu and δ opioid receptor alter circuit activity in these regions. As opioids are well known to strongly regulate these circuits determining exactly where in these circuits these receptors act to gate thalamo-cortical activity into the striatum is a significant advance. The authors make good use of two color ChR2 (chrimson/chronos) to determine that MORs but not DORs strongly inhibit medial thalamic glutamatergic inputs to the DMS and ACC, and that a proportion of mThal neurons that project to the ACC also project to the DMS. They go on to show that within this circuit DORs are expressed primarily on PV interneurons in the ACC where they function to regulate feed-foreward inhibition into the ACC. Finally, using the clever combination of cell attached recordings and dual recordings in the ACC and DMS they show that MORs inhibit thalamo-cortical-striatal circuits while DORs alternatively disinhibit these circuits.

The experiments and controls have been performed well and carefully analyzed/interpreted. Based on the work provided in the manuscript and supplemental figures I believe that the conclusions are well justified and no further experiments are required. The exciting aspect of this work is that marks a significant advance in furthering our understanding of how opioids mechanistically can alter circuit activity that likely underlies the affective-motivational aspects of pain processing. Together, with the carefully performed experiments and well written manuscript make it appropriate for publication in *eLife*.

My only suggestion relates to the presentation of data in Figure 3. It was unclear what proportion of MSNs exhibited an EPSC when AAV2-retro-Cre was injected into the AAC and AAV-DiO-ChR2 was injected into the MThal (Figure 3E,F)? A scatter plot of the responders/non-responders of MSNs that exhibited EPSCs would be informative. As EPSCs are much smaller than previous figures from mThal injections it seems as though a relatively small numbers of cells projecting to the ACC also project to the DMS. Further describing the proportion of cells in the DMS exhibited EPSCs would help show the distribution of cells that receive input from mThal cells that also project to the ACC.

*Reviewer \#2:*

The manuscript by Birdsong et al., investigates the influence of opioid receptor activation on separate afferents to spiny projection neurons in the striatum. The anterior cingulate cortex and the medial thalamus projections were individually stimulated by optogenetic activation of either Chrimson or ChR2. The mThal to Str pathway was sensitive to mu receptor agonism whereas the ACC to Str pathway was insensitive to both MOR and DOR activation. However, the mThal to ACC projection was sensitive to MOR activation. This creates a circuit whereby mThal afferents synapsing directly on ACC pyramidal neurons are sensitive to MOR while inhibitory interneurons in the ACC are sensitive to DOR. This is an exciting finding as it shows the differential effect that DOR and MOR can have on spiny projection neurons in the dorsal medial striatum. This can have translational applications in the use of opioids with higher affinities for either DORs or MORs.

Although different opioids may have differing effects, it is difficult to discern what the endogenous effect of opioids may be on the circuit. MOR activation on MThal to ACC pyramidal pathway causes a decrease in EPSC amplitude and a decrease in IPSC amplitude. Meanwhile, DOR activation causes a decrease in IPSC amplitude in ACC pyramidal neurons. What is the net effect on firing?

It is surprising that, given the substantial circuit differences from D1 and D2 spiny projection neuron activation, that D1 and D2 SPNs were not identified.

Although the differential effect of MOR agonist alleviates this concern, it is nonetheless preferable to have an independent measure that each laser activates distinct pathways. When activating the 470 laser and the 625 laser simultaneously, the currents should summate linearly if they are from distinct inputs.

*Reviewer \#3:*

This paper addresses how we can understand the overall effect of different opioid receptor activity acting at multiple sites within important brain circuits. The optogenetic stimulation of multi-synaptic responses in striatal neurons allows direct testing of these circuit effects rather than inference from responses at multiple sites which is a significant advance.

I have a few concerns about the experiments included in some experiments and data that either wasn\'t included or experiments not performed.

I have some concerns about the lack of reversal (due to no application of antagonist) or application of antagonist that does not reverse the opioid inhibition of the synaptic response/firing of the cell. For some experiments the data is very clear, good inhibition with an agonist and full reversal with an antagonist, for example at the mthal-str synapses in figure 2. However, in several other experiments neurons are included in the analysis where the opioid inhibition is not reversed by the antagonist. For example, Figure 4C,F; Figure 4---figure supplement 1C,F, Figure 5C. There also appear to be cells that have a data point for the agonist but without a connected data point for the antagonist. For example, Figure 4---figure supplement 1, Figure 4C,F, Figure 5. Of particular concern is the data shown in figure 4f which is pivotal to the interpretation of the data presented in this study. The effect of DPDPE on the IPSC seems very variable. In some cells the agonist inhibited the response and this was sometimes reversed, sometimes no antagonist response is shown (for largest inhibition) and in some cases the antagonist produced a large overshoot in the size of the synaptic. There only appears to be one cell where δ receptor activation reduces the size of the IPSC and this is reversed to baseline by the antagonist. How can you be confident that the changes in synaptic responses were due to activation of the relevant opioid receptor if they were not reversed by the relevant antagonist? This needs to be resolved and if there is a biological basis for it, rather than experimental, it would be interesting to see it discussed.

In other experiments antagonist reversals are not shown. For example, data depicted in Figure 6 and Figure 7. This reduces the confidence in this data.

It would also have been interesting to see the effect of MOR activation in the experiment using light activation in the ACC presented in Figure 7. This would have further tested the model of how opioids are acting in this circuit.

The authors suggest that overall activation of the striatum will determine whether the person experiences the affective aspect of pain (Introduction). Is there evidence that activation of the striatum, regardless of whether this come from the thalamus or cortex, is aversive? Or do the different inputs to the striatum result in a different experience of the aversive component of pain?

10.7554/eLife.45146.019

Author response

> Essential revisions:
>
> The following points must be addressed before final acceptance of the manuscript. Most of these concerns can be addressed with additional analysis, modifications of the figures and extension of the discussion. For your understanding of these essential revisions, the full reviews are appended below.
>
> 1\) In Figure 3E,F, it is unclear what proportion of MSNs exhibited an EPSC when AAV2-retro-Cre was injected into the AAC and AAV-DiO-ChR2 was injected into the MThal. Further describing the proportion of cells in the DMS exhibited EPSCs would help show the distribution of cells that receive input from mThal cells that also project to the ACC. A scatter plot of the responders/non-responders of MSNs that exhibited EPSCs would be informative.

We agree with the reviewers that the question of how frequently ACC-projecting MThal inputs synapse to the MSNs in the DMS is an interesting one but might not be possible to address with the limitation of existing reagents and methods. This is mainly due to two factors, both of which affect the interpretation of non-responders. (1) The existing retrograde viruses, including rAAV2-retro we used here, have been improved in terms of label efficiency but are far from 100%. Therefore, we cannot virally infect all axons within the ACC that arise from the MThal by our viral combination of rAAV2-retro expressing Cre-recombinase in the ACC and AAV2 expressing DIO-ChR2-EYFP in the MThal. As a result, if an MSN does not exhibit an EPSC upon light stimulation, it does not necessarily mean that it is not receiving ACC-projecting MThal inputs. (2). Whether an EPSC, thus a synaptic connection, can be detected also depends on the expression level of ChR2, which can vary across animals, and is a known caveat of the optogenetic tools. The smaller EPSCs we observed in these experiments (Figure 3F) relative to other experiments (Figure 1C and Figure 2B) is likely due to the low efficiency of the retrograde Cre-recombinase expression in the MThal cells which resulted in much lower expression level of ChR2 in the MThal compared to that expression observed in other experiments.

In summary, given the limitation of the current technology and intersectional nature of this experiment, in our system, the lack of EPSCs does not lead to the conclusion of lack of bona fide synaptic connections. Therefore, we feel that in this case, the scatter plot will not address the question the reviewer is interested in. In the meantime, we now emphasize in the main text that what we can claim is the existence of the ACC-projecting MThal neurons which also project to the MSN in the DMS, and this projection is sensitive to enkephalin (subsection "Thalamostriatal and thalamocortical projections can arise from the same medial thalamic neuronal population").

> 2\) There is concern about the lack of reversal (due to no application of antagonist) or application of antagonist that does not reverse the opioid inhibition of the synaptic response/firing of the cell. In several experiments neurons are included in the analysis where the opioid inhibition is not reversed by the antagonist (e.g. figure 4C,F; Figure 4---figure supplement 1C,F, Figure 5C). There also appear to be cells that have a data point for the agonist but without a connected data point for the antagonist. For example, Figure 4---figure supplement 1, Figure 4C,F, Figure 5. Of particular concern is the data shown in Figure 4F which is pivotal to the interpretation of the data presented in this study. The effect of DPDPE on the IPSC seems very variable. In some cells the agonist inhibited the response and this was sometimes reversed, sometimes no antagonist response is shown (for largest inhibition) and in some cases the antagonist produced a large overshoot in the size of the synaptic current. There only appears to be one cell where δ receptor activation reduces the size of the IPSC and this is reversed to baseline by the antagonist. How could these changes in synaptic responses be due to activation of the relevant opioid receptor if they were not reversed by the relevant antagonist? If there is a biological basis for it, rather than experimental, it would be interesting to see it discussed.

We believe that the variability in effect of DPDPE on the IPSCs is a mix of experimental limitations in this biological system. First, the IPSCs are generally large and disynaptic or polysynaptic meaning small changes in excitability can have large effects. If the IPSCs are polysynaptic, inhibiting the PV cells would lead to disinhibition of other pyramidal cells which may in turn excite more PV cells as a negative feedback. Because a small number of PV cells densely innervate pyramidal cells, adding or losing the input of a single PV cell can have a large effect on IPSC amplitude particularly when the frequency of optical stimulation is low and the number of trials that are averaged is limited.

We have established standards for recording quality and health of cells. In some experiments, cell health or recording criteria did not hold long enough for a full set of pharmacology experiments, e.g., only agonists were added and no antagonists were added. We still include those cells with the part that all criteria were met. That is why some data points did not have antagonist data (these data points lack a gray dashed line). For this reason, we were very careful with our statistical analyses and utilized steps to specifically deal with the unmatched data points. As stated in subsection "Quantification and Statistical Analysis", "The Skillings-mack test is a non-parametric test, which allows for missing data points (unbalanced design)."

The lack of reversal in some examples may be due to incomplete reversal as a result of competition between DPDPE and naltrindole. Additionally, desensitization or rundown of the channelrhodopsin currents in the MThal to PV synapses may also contribute to the non-full reversal with antagonists. In combination with the notion above that small changes in the EPSP amplitude evoked in putative PV neurons could bring the PV cells below action potential threshold, a small change in channel rundown can have a major effect in this experimental setup.

In addition, these experiments involve stepping the membrane potential between -60 mV and +5 mV. There was potentially some contamination of the IPSCs with EPSCs as a small inward current is noticeable in the example traces in Figure 4E. Small drift in the actual holding potential or changes in space clamping over the experiment could also result in slight changes of the relative contributions of EPSCs and IPSCs, and thus the peak amplitude of the IPSCs measured.

In Figure 5, multiple possibilities also exist for some non-full reversal effects. We believe that the reversal of DPDPE inhibition by naltrindole is slow, and therefore may not have been completely reversed in a timeframe relevant for these experiments. This could be due to kinetics of competition binding, or the inhibition may be mediated in part by kinase activity which can have effects after G-protein signaling is terminated. In addition, some other forms of plasticity could be induced by DOR activation which would be slow to reverse on the timescale of these experiments.

We do want to experimentally address whether the issue is due to non-specific effects of the pharmacological reagents we used. The rationale is that one potential possibility of the partial irreversibility is because DPDPE may modulate synaptic transmission via DOR-independent pathway, therefore DOR antagonist naltrindole would not able to reverse the DPDPE-mediated modulation of IPSCs. Therefore, we have performed an additional experiment which is to repeat the experiments shown in Figure 4D-F, except that we applied DOR-antagonist naltrindole first, followed by DOR-agonist DPDPE. AAV2-CAG-ChR2(H134R)-TdTomato virus was injected in the MThal, and feed-forward inhibitory inputs to L5 pyramidal neurons the ACC were evaluated (Figure 4---figure supplement 3). We recorded optically-evoked IPSCs (oIPSCs), and first perfused DOR-antagonist naltrindole followed by DOR-agonist DPDPE. Naltrindole pre-treatment prevented the DPDPE-mediated modulation of oIPSC, as observed in Figure 4 and Figure 5, (Figure 4---figure supplement 3), indicating that DPDPE modulates GABAergic neurotransmission via a DOR-dependent pathway.

> 3\) The authors suggest that overall activation of the striatum will determine whether the person experiences the affective aspect of pain (Introduction). Is there evidence that activation of the striatum, regardless of whether this comes from the thalamus or cortex, is aversive? Or do the different inputs to the striatum result in a different experience of the aversive component of pain?

We thank the reviewers for pointing this out. Our original rationale was that since both increased ACC and medial thalamic activities are known to be associated with pain perception (e.g., Casey et al., 1994; Davis et al., 1997; Peyron et al., 1999, Peyron et al., 2000), and these two regions most strongly converge in the DMMS (Hunnicutt et al., 2016), we predicted that decreased activity of these terminals in the DMS would be involved in pain relief, though this has not been directly demonstrated to our knowledge. We have now re-worded this part to reflect that MOR and DOR activation is predicted to modulate pain responses in opposite ways (Introduction, "Thus, MOR and DOR activation are predicted to play opposite roles in pain processing mediated by this thalamo-cortico-striatal circuit"), and we think this is better reflective of our data and current knowledge.

> 4\) It is surprising that, given the substantial circuit differences from D1 and D2 spiny projection neuron activation, that D1 and D2 SPNs were not identified. Although the differential effect of MOR agonist alleviates this concern, it is nonetheless preferable to have an independent measure that each laser activates distinct pathways. When activating the 470 laser and the 625 laser simultaneously, the currents should sum linearly if they are from distinct inputs.

We agree with the reviewers that investigating cell type-specific effects onto D1 and D2 MSNs would be interesting. So far, under our experimental conditions, we have not observed obvious heterogeneous responses, at least not a bi-modal distribution as one might expect if there are major differences in D1 versus D2 responses, of opioid inhibition of MThal inputs to the MSNs, indicating that inputs to both D1 and D2 MSNs might be modulated in a similar fashion ([Author response image 1](#respfig1){ref-type="fig"}). Previous work comparing the excitatory input kinetics between D1 and D2 MSNs suggest that the risetime of mEPSCs are slower in D2 MSNs (Al-muhtasib et al., 2018). If the DAMGO effect on EPSC amplitude is different between D1 versus D2 MSNs, a correlation is expected between baseline EPSC risetime and DAMGO effect on EPSC amplitude in our data. Under current conditions, no significant correlation between DAMGO effect on EPSC amplitude and baseline EPSC risetime obtained from all MSNs is observed ([Author response image 1B](#respfig1){ref-type="fig"}). Furthermore, comparison of two putative MSN subpopulations, defined using a cluster analysis among all recorded MSNs based on the baseline EPSC kinetics (Figure 4---figure supplement 3C), yielded non-significantly different distributions of DAMGO effect on EPSC (Figure 4---figure supplement 3D). Together, this suggests that so far, there is no evidence that observed mu-opioid mediated suppression of thalamostriatal inputs is dependent on the identity of the recorded MSN. We think the systematic investigation of cell-type specific response is beyond the scope of current manuscript but an interesting question for future investigation. We have now added a notion that we have not observed any evidence for opioids' modulation of the thalamic inputs that suggest potential D1 and D2 MSN specific effects (subsection "Opioid modulation of the thalamo-cortico-striatal circuitry").

![No clear bi-modal or two population effects detected in MOR-mediated suppression of thalamostriatal inputs to the MSNs in the DMS.\
(**a**) Histogram of cell distribution based on effects of mu-opioid agonist DAMGO on optically-evoked excitatory postsynaptic current (EPSC) amplitude recorded in the MSNs; n = 40 neurons from 25 mice. The observed DAMGO effects had a non-normal distribution (Shapiro-Wilk normality test, *W* = 0.8219, p \< 0.001), but showed no clear bi-modal distribution of two roughly equal populations. (**b**) Plot of the DAMGO effects on baseline oEPSC amplitude recorded from MSNs as a function of risetime of the baseline EPSC. There was no correlation between EPSC risetime and degree of EPSC inhibition by DAMGO. Linear regression model (red dash line), R^2^ = 0.018, F (1, 38) = 0.677, p = 0.416. (c-d) In case two populations exist within the recorded MSNs, we wanted to test whether the effect of DAMGO on baseline EPSC amplitude was significantly different in the two populations defined based on baseline EPSC parameters. (**c**) Agglomerative hierarchical cluster analysis based on Pearson correlation between baseline EPSC parameters (columns), and Euclidean distance between recorded MSNs (rows), with heatmap representing centered/standardized values (x-x-σ). Two main clusters were defined (cluster 1: red n = 16 neurons/11 mice, cluster 2: blue n = 23 neurons/17 mice) based on baseline EPSC parameters, representing putative subpopulations among the recorded MSNs. (**d**) Histograms of cell distributions based on DAMGO effects on baseline recorded from the MSNs defined in cluster 1 or 2, red or blue, respectively. Mann-Whitney U test, *U* = 204, p = 0.751.](elife-45146-resp-fig1){#respfig1}

Regarding the dual channelrhodopsin activation experiments, we addressed the potential cross-activation of Chrimson with 470 nm excitation in Figure 1---figure supplement 1D-E by expressing each channelrhodopsin variant separately in individual animals, and stimulated with both the 470 nm and 625 nm excitation. From these data the degree of cross-activation was estimated to be very low (approximately 4% for Chrimson by 470 nm, and \< 1% for ChR2 and CsChR by 625 nm). We feel that the cross-activation data together with the data demonstrating a clear inhibition of the 470 nm-evoked currents by DAMGO with no effects on the 625 nm-evoked currents should alleviate the concern of unintended activation with 625 nm light. To further verify our results and conclusions that specific opioid receptor types modulate distinct inputs to the striatum we performed independent control experiments as shown in Figure 1---figure supplement 2. In these experiments individual projection origins, i.e. ACC, PFC, AMThal, and MThal, were injected with only one ChR2 variant, CsChR, and subsequently tested their sensitivity to opioid modulation. We confirmed that DAMGO specifically modulated the thalamostriatal projections, and therefore that these projections represent functionally and pharmacologically distinct inputs compared to the corticostriatal projections. Thus, we feel confident that there was very little cross talk and any potential cross-activation did not change any interpretations of the data.

We did not attempt the additivity analysis suggested due to the fact that the activation of Chrimson by 470 nm light is still not 0 (as mentioned above, 4%; Figure 1---figure supplement 1). While the low intensity of 470 nm stimulation we used may not evoke large EPSCs, we cannot exclude the possibility that 470 nm and 625 nm light together lead to non-linear effects for reasons beyond our current understanding of these tools.

> 5\) Does Figure 6B show action potentials? These must be escaped action currents. Nevertheless, they appear to have half-widths of 3 ms. Using escaped action currents as a measure of firing rate may be affected by the \"voltage command\" even when not broken in to the whole-cell mode.

Figure 6B shows action currents recorded in cell-attached mode. Voltage clamp mode setting on the amplifier was used and the voltage command was set and adjusted when needed during the experiment, to obtain an amplifier current of 0 pA. This approach ensures that the spike activity of the recorded neuron was not influenced by the cell-attached mode settings, since no current is flowing between the cell and electrode (Perkins, 2006). The firing rate therefore should not be affected by the voltage command. In addition, quantification of the action potential widths (width at half-max action current amplitude, [Author response image 2](#respfig2){ref-type="fig"}) during baseline and agonist applications (DAMGO and DPDPE) were combined, showing that the mean action potential width is 1.36 ms, consistent with the reported action potential widths in L5 pyramidal neurons in the mouse ACC (1.13 ms, Lee et al., 2007) and in L5 pyramidal neurons in the neocortex (2.08 ms, see neuronelectro.org). In conclusion, the recorded currents resemble action potentials with expected kinetics, which remain stable during the recording and therefore, we do not have evidence that 'voltage command' in cell-attached mode affect our results.

![Action potential widths remain stable during cell-attached recording and they are comparable to other studies in the L5 pyramidal neurons on the cortex.\
Summary data of median full width at half-maximum of action potential currents recorded in L5 pyramidal neurons of the ACC; n = 14 neurons from 5 mice. The agonists (DAMGO or DPDPE) did not change the recorded action potential current width; Mann-Whitney U test *U* = 189, p = 0.5320.](elife-45146-resp-fig2){#respfig2}

> 6\) Do the specific MThal inputs to ACC synapse on the ACC projections to DMS?

To answer the question, we have performed additional experiments to record from the L5 pyramidal neurons in the ACC that project to the DMS to test whether they receive MThal inputs ([Author response image 3](#respfig3){ref-type="fig"}). To label the DMS-projecting L5 pyramidal neurons in the ACC ([Author response image 3A-B](#respfig3){ref-type="fig"}), we injected retrograde beads in the DMS; and to optically stimulate the MThal inputs, we injected AAV2-CAG-ChR2(H134R)-tdTomato in the MThal of the same animal ([Author response image 3A](#respfig3){ref-type="fig"}). From all recorded DMS-projecting L5 pyramidal neurons, \~91.7% (11 out of 12 neurons) received MThal inputs ([Author response image 3C](#respfig3){ref-type="fig"}) with a charge transfer and onset value within the range of EPSCs reported in the main text ([Author response image 3C-D](#respfig3){ref-type="fig"}, see also Figure 4---figure supplement 2C and Figure 7---figure supplement 1A). These results indicate that indeed, MThal inputs to ACC synapse onto the DMS-projecting neurons in the ACC.

![The DMS-projecting L5 pyramidal neurons in the ACC receive direct inputs from the MThal.\
(**a**) Experimental schematic showing retrogradely-transported beads (retrobeads) injection in the DMS to retrogradely-label DMS-projecting pyramidal neurons (Pyr) in the ACC, and AAV2/1-CAG-ChR2(H134R)-tdTomato injection in the MThal to allow for optical stimulation of specific thalamic inputs to the ACC. (**b**) Representative brightfield (left panel) and fluorescent (center panel) images of an ACC layer 5 (L5) with retrobeads present in the soma (merge, right panel). (**c**) Averaged optically-evoked excitatory postsynaptic currents (EPSCs, average of 12 single trials) of all individual bead-positive L5 pyramidal neurons recorded in the DMS/MThal injected mice (n = 12 neurons from 4 mice). 11 out of 12 recorded cells (black traces) received inputs from the MThal, defined as peak amplitude \> (mean baseline + 5 x standard deviation). Grey trace: non-responding L5 pyramidal neuron. Blue bar: 1 ms of 470 nm light stimulation. (**d**) Quantification of the EPSC charge transfer of all recorded EPSCs as shown in B. (**e**) Quantification of EPSC onset time of all recorded EPSCs as shown in B. Box plot with median, first and third quartile and whiskers represent 1.5 times interquartile range.](elife-45146-resp-fig3){#respfig3}

> 7\) Although different opioids may have differing effects, it is difficult to discern what the endogenous effect of opioids may be on the circuit. MOR activation on MThal to ACC pyramidal pathway causes a decrease in EPSC amplitude and a decrease in IPSC amplitude. Meanwhile, DOR activation causes a decrease in IPSC amplitude in ACC pyramidal neurons. What is the net effect on firing?

We agree with the reviewers that the endogenous effect of opioids is an import question and a future direction to take. However, addressing the endogenous effects of opioid receptor activation is currently difficult and is beyond the scope of the current work. The main obstacle for addressing this question is the ability to reliably release and quantify the release of endogenous opioids, e.g., enkephalin or dynorphin in mouse brain slice. We did attempt to trigger release of enkephalin in transgenic mouse lines, which expressed channelrhodopsin in putative enkephalin-releasing cells (*PENK-IRES2-Cre;Ai32* mice). Unfortunately, it was difficult to establish the reliable stimulation protocols for enkephalin release due to lack of reliable ways to measure enkephalin release. For the same reason, it is difficult to pharmacologically address the net effects on firing without knowing whether/how the endogenous opioid receptor is activated. These pharmacological agents, e.g. enkephalins, endorphins and dynorphins, have differential affinities for mu, δ and kappa opioid receptors, though the affinity differences can be minimal between mu and δ receptors (e.g. Raynor et al., 1994). Differences in affinity, the sites of action, and the concentration of endogenous agonists will together determine the net effect of firing in the ACC. Based on our findings, our prediction is that at modest concentrations of endogenous opioid receptor ligands with highest affinities for MORs preferably reduce ACC firing, and therefore suppress both direct thalamostriatal and the indirect thalamo-cortico-striatal pathways, whereas those endogenous ligands with highest affinities for DORs, at relatively selective concentrations increase ACC firing. Because IPSCs are sensitive to both mu and δ agonists, low to moderate concentrations of non-selective agonists would be predicted to impact feed-forward inhibition more profoundly and have a net excitatory effect, while higher concentration would greatly diminish EPSCs producing a net inhibitory effect. The future work that measures the endogenous ligand release sites and concentrations will provide key information for answering these questions. Since the direct testing of these predictions is not feasible with our current means, and the related topic might be work of its own in the future, we have not included major discussions but have added a short one to this point (subsection "Opposing effects of opioid subtypes on circuitry modulation").

[^1]: Department of Pharmacology, University of Michigan, Ann Arbor, United States.

[^2]: These authors contributed equally to this work.
